ERBB3 and ITK |
erb-b2 receptor tyrosine kinase 3 |
IL2-inducible T-cell kinase |
|
- TCR signaling
- Generation of second messenger molecules
- Fc epsilon receptor (FCERI) signaling
- FCERI mediated Ca+2 mobilization
- Innate Immune System
- Adaptive Immune System
|
|
|
|
|
ERBB3 and TNS3 |
erb-b2 receptor tyrosine kinase 3 |
tensin 3 |
|
|
|
|
|
|
ERBB3 and CD82 |
erb-b2 receptor tyrosine kinase 3 |
CD82 molecule |
|
|
|
|
|
|
ERBB3 and TXK |
erb-b2 receptor tyrosine kinase 3 |
TXK tyrosine kinase |
|
- Fc epsilon receptor (FCERI) signaling
- FCERI mediated Ca+2 mobilization
- Innate Immune System
|
|
|
|
|
ERBB4 and SYK |
erb-b2 receptor tyrosine kinase 4 |
spleen tyrosine kinase |
|
- Signaling by the B Cell Receptor (BCR)
- FCERI mediated MAPK activation
- Platelet Aggregation (Plug Formation)
- DAP12 signaling
- Regulation of signaling by CBL
- Role of phospholipids in phagocytosis
- Fcgamma receptor (FCGR) dependent phagocytosis
- FCGR activation
- Regulation of actin dynamics for phagocytic cup formation
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- DAP12 interactions
- Integrin alphaIIb beta3 signaling
- Cytokine Signaling in Immune system
- Role of LAT2/NTAL/LAB on calcium mobilization
- Signaling by Interleukins
- Fc epsilon receptor (FCERI) signaling
- GPVI-mediated activation cascade
- Interleukin-2 signaling
- FCERI mediated Ca+2 mobilization
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
|
|
- Staurosporine
- N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide
- 6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one
- 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide
- 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide
- Ellagic Acid
|
|
|
ERBB4 and NRG3 |
erb-b2 receptor tyrosine kinase 4 |
neuregulin 3 |
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- GRB2 events in ERBB2 signaling
- PI-3K cascade
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signaling by PDGF
- Signalling by NGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by ERBB4
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- Nuclear signaling by ERBB4
- SHC1 events in ERBB4 signaling
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
|
|
|
|
ESR1 and HNF4A |
estrogen receptor 1 |
hepatocyte nuclear factor 4, alpha |
- Nuclear signaling by ERBB4
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
- Signaling by ERBB4
|
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Diethylstilbestrol
- Chlorotrianisene
- Conjugated Estrogens
- Etonogestrel
- Desogestrel
- Levonorgestrel
- Progesterone
- Raloxifene
- Toremifene
- Medroxyprogesterone
- Estrone
- Tamoxifen
- Estradiol
- Ethynodiol Diacetate
- Clomifene
- Dienestrol
- Fulvestrant
- Norgestimate
- Ethinyl Estradiol
- Melatonin
- Trilostane
- Naloxone
- Fluoxymesterone
- Estramustine
- Mestranol
- Danazol
- Allylestrenol
- Genistein
- Compound 19
- Compound 18
- Compound 4-D
- 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
- 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
- Estriol
- Estropipate
- Quinestrol
- Ospemifene
- 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
- 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol
- [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
- (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
- (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
- 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
- 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
- DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
- 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE
- 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
- RALOXIFENE CORE
|
|
|
|
ESR1 and PPARG |
estrogen receptor 1 |
peroxisome proliferator-activated receptor gamma |
- Nuclear signaling by ERBB4
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
- Signaling by ERBB4
|
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- Diethylstilbestrol
- Chlorotrianisene
- Conjugated Estrogens
- Etonogestrel
- Desogestrel
- Levonorgestrel
- Progesterone
- Raloxifene
- Toremifene
- Medroxyprogesterone
- Estrone
- Tamoxifen
- Estradiol
- Ethynodiol Diacetate
- Clomifene
- Dienestrol
- Fulvestrant
- Norgestimate
- Ethinyl Estradiol
- Melatonin
- Trilostane
- Naloxone
- Fluoxymesterone
- Estramustine
- Mestranol
- Danazol
- Allylestrenol
- Genistein
- Compound 19
- Compound 18
- Compound 4-D
- 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
- 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
- Estriol
- Estropipate
- Quinestrol
- Ospemifene
- 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
- 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol
- [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
- (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
- (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
- 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
- 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
- DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
- 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE
- 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
- RALOXIFENE CORE
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
ESR2 and PPARG |
estrogen receptor 2 (ER beta) |
peroxisome proliferator-activated receptor gamma |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- Diethylstilbestrol
- Raloxifene
- Tamoxifen
- Estradiol
- Trilostane
- Estramustine
- Genistein
- Para-Mercury-Benzenesulfonic Acid
- N-Butyl-11-[(7r,8r,9s,13s,14s,17s)-3,17-Dihydroxy-13-Methyl-7,8,9,11,12,13,14,15,16,17-Decahydro-6h-Cyclopenta[a]Phenanthren-7-Yl]-N-Methylundecanamide
- 5-Alpha-Androstane-3-Beta,17beta-Diol
- 4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol
- Estriol
- Estropipate
- 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL
- 3-(3-FLUORO-4-HYDROXYPHENYL)-7-HYDROXY-1-NAPHTHONITRILE
- [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
- 4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL
- 2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL
- 2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL
- (3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol
- 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL
- 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME
- 5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE
- 3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE
- 3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL
- (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- (16ALPHA,17ALPHA)-ESTRA-1,3,5(10)-TRIENE-3,16,17-TRIOL
- (9aS)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
FABP1 and PPARG |
fatty acid binding protein 1, liver |
peroxisome proliferator-activated receptor gamma |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
FBLN1 and TCF7L2 |
fibulin 1 |
transcription factor 7-like 2 (T-cell specific, HMG-box) |
- Molecules associated with elastic fibres
- Elastic fibre formation
|
- APC truncation mutants have impaired AXIN binding
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- binding of TCF/LEF:CTNNB1 to target gene promoters
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- S37 mutants of beta-catenin aren't phosphorylated
- Peptide hormone metabolism
- Degradation of beta-catenin by the destruction complex
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Incretin synthesis, secretion, and inactivation
- truncations of AMER1 destabilize the destruction complex
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- repression of WNT target genes
- beta-catenin independent WNT signaling
- deletions in the AMER1 gene destabilize the destruction complex
- Ca2+ pathway
- AMER1 mutants destabilize the destruction complex
- TCF dependent signaling in response to WNT
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
|
|
|
|
|
FKBP4 and PTPN2 |
FK506 binding protein 4, 59kDa |
protein tyrosine phosphatase, non-receptor type 2 |
- HSF1-dependent transactivation
- Attenuation phase
- Cellular response to heat stress
|
|
|
|
|
|
FOXO1 and PPARG |
forkhead box O1 |
peroxisome proliferator-activated receptor gamma |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- Regulation of beta-cell development
- PI-3K cascade
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signaling by PDGF
- DAP12 interactions
- Signalling by NGF
- GAB1 signalosome
- AKT-mediated inactivation of FOXO1A
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- AKT phosphorylates targets in the nucleus
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Regulation of gene expression in beta cells
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
FOXO1 and HNF4A |
forkhead box O1 |
hepatocyte nuclear factor 4, alpha |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- Regulation of beta-cell development
- PI-3K cascade
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signaling by PDGF
- DAP12 interactions
- Signalling by NGF
- GAB1 signalosome
- AKT-mediated inactivation of FOXO1A
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- AKT phosphorylates targets in the nucleus
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Regulation of gene expression in beta cells
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
|
|
|
|
FLNA and SH2B3 |
filamin A, alpha |
SH2B adaptor protein 3 |
- Cell junction organization
- GP1b-IX-V activation signalling
- Response to elevated platelet cytosolic Ca2+
- Platelet degranulation
- Platelet activation, signaling and aggregation
- Cell-extracellular matrix interactions
|
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Factors involved in megakaryocyte development and platelet production
|
|
|
|
|
FLNA and MTNR1B |
filamin A, alpha |
melatonin receptor 1B |
- Cell junction organization
- GP1b-IX-V activation signalling
- Response to elevated platelet cytosolic Ca2+
- Platelet degranulation
- Platelet activation, signaling and aggregation
- Cell-extracellular matrix interactions
|
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- Signaling by GPCR
- GPCR downstream signaling
- Class A/1 (Rhodopsin-like receptors)
- G alpha (i) signalling events
- Metabolic disorders of biological oxidation enzymes
- GPCR ligand binding
|
|
- Ramelteon
- Melatonin
- Agomelatine
|
|
|
FOS and HNF1A |
FBJ murine osteosarcoma viral oncogene homolog |
HNF1 homeobox A |
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Cellular Senescence
- FCERI mediated MAPK activation
- Toll Like Receptor TLR6:TLR2 Cascade
- Activated TLR4 signalling
- Toll Like Receptor TLR1:TLR2 Cascade
- Activation of the AP-1 family of transcription factors
- MyD88 cascade initiated on plasma membrane
- Toll Like Receptor 5 (TLR5) Cascade
- MyD88 dependent cascade initiated on endosome
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- Toll Like Receptor 9 (TLR9) Cascade
- Innate Immune System
- TRIF-mediated TLR3/TLR4 signaling
- MAP kinase activation in TLR cascade
- Senescence-Associated Secretory Phenotype (SASP)
- MyD88-independent cascade
- Toll Like Receptor 2 (TLR2) Cascade
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Oxidative Stress Induced Senescence
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Fc epsilon receptor (FCERI) signaling
- MAPK targets/ Nuclear events mediated by MAP kinases
|
- Regulation of beta-cell development
- Regulation of gene expression in beta cells
|
|
|
|
|
FOSL2 and CREB5 |
FOS-like antigen 2 |
cAMP responsive element binding protein 5 |
|
|
|
|
|
|
FYN and CD226 |
FYN proto-oncogene, Src family tyrosine kinase |
CD226 molecule |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- DCC mediated attractive signaling
- Netrin mediated repulsion signals
- Signaling by EGFRvIII in Cancer
- Nef and signal transduction
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Regulation of KIT signaling
- PI3K/AKT activation
- PI-3K cascade
- EPH-Ephrin signaling
- Fcgamma receptor (FCGR) dependent phagocytosis
- FCGR activation
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Host Interactions of HIV factors
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- The role of Nef in HIV-1 replication and disease pathogenesis
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- Signaling by VEGF
- Downstream signal transduction
- Sema3A PAK dependent Axon repulsion
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
- CRMPs in Sema3A signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- Platelet Adhesion to exposed collagen
- Axon guidance
- Costimulation by the CD28 family
- PIP3 activates AKT signaling
- HIV Infection
- VEGFA-VEGFR2 Pathway
- EPHB-mediated forward signaling
- EPHA-mediated growth cone collapse
- Ephrin signaling
- EPH-ephrin mediated repulsion of cells
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- NCAM signaling for neurite out-growth
- Netrin-1 signaling
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- Signalling by NGF
- Semaphorin interactions
- CTLA4 inhibitory signaling
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- PECAM1 interactions
- CD28 dependent Vav1 pathway
- Signaling by FGFR
- Cell surface interactions at the vascular wall
- GPVI-mediated activation cascade
|
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- Adaptive Immune System
|
- Dasatinib
- 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane
|
|
|
|
FYN and PRKCQ |
FYN proto-oncogene, Src family tyrosine kinase |
protein kinase C, theta |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- DCC mediated attractive signaling
- Netrin mediated repulsion signals
- Signaling by EGFRvIII in Cancer
- Nef and signal transduction
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Regulation of KIT signaling
- PI3K/AKT activation
- PI-3K cascade
- EPH-Ephrin signaling
- Fcgamma receptor (FCGR) dependent phagocytosis
- FCGR activation
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Host Interactions of HIV factors
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- The role of Nef in HIV-1 replication and disease pathogenesis
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- Signaling by VEGF
- Downstream signal transduction
- Sema3A PAK dependent Axon repulsion
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
- CRMPs in Sema3A signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- Platelet Adhesion to exposed collagen
- Axon guidance
- Costimulation by the CD28 family
- PIP3 activates AKT signaling
- HIV Infection
- VEGFA-VEGFR2 Pathway
- EPHB-mediated forward signaling
- EPHA-mediated growth cone collapse
- Ephrin signaling
- EPH-ephrin mediated repulsion of cells
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- NCAM signaling for neurite out-growth
- Netrin-1 signaling
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- Signalling by NGF
- Semaphorin interactions
- CTLA4 inhibitory signaling
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- PECAM1 interactions
- CD28 dependent Vav1 pathway
- Signaling by FGFR
- Cell surface interactions at the vascular wall
- GPVI-mediated activation cascade
|
- G alpha (q) signalling events
- Signaling by GPCR
- Downstream TCR signaling
- Axon guidance
- Effects of PIP2 hydrolysis
- FCERI mediated NF-kB activation
- Inactivation, recovery and regulation of the phototransduction cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- The phototransduction cascade
- Programmed Cell Death
- G alpha (z) signalling events
- Netrin-1 signaling
- Innate Immune System
- Apoptotic cleavage of cellular proteins
- Apoptotic execution phase
- Diseases associated with visual transduction
- G alpha (q) signalling events
- GPCR downstream signaling
- TCR signaling
- Visual phototransduction
- Fc epsilon receptor (FCERI) signaling
- Platelet activation, signaling and aggregation
- Adaptive Immune System
|
- Dasatinib
- 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane
|
- Staurosporine
- Phosphonothreonine
- Phosphonoserine
|
|
|